GTP Bioways
French biologics CDMO headquartered in Toulouse offering end-to-end development, GMP manufacturing, and fill-finish services for monoclonal antibodies, recombinant proteins, ADCs, and nanodrugs to biopharma and biotech clients; acquired by Olon Group in November 2024 and rebranded Olon France.
- Company typePrivate
- Founded2000
- HeadquartersToulouse, France
- Headcount51–100
- GTM typeB2B
- OfferingServices
What GTP Bioways does
GTP Bioways is a French contract development and manufacturing organization (CDMO) headquartered in Toulouse that provides end-to-end services for the development, process optimization, and GMP manufacturing of complex biologics. The company operates from four French sites (Toulouse, Saint-Julien, Labège, and Veyre-Monton) and supports programs across multiple expression systems, including mammalian (CHO), microbial (E. coli, P. pastoris), and insect cells. Its portfolio covers late discovery services, process and analytical development, GMP manufacturing for preclinical, clinical, and small commercial batches, and in-house aseptic fill and finish.
The company specializes in five therapeutic molecule classes: monoclonal antibodies, recombinant proteins, bispecifics, antibody-drug conjugates (ADCs), and nanodrugs. Differentiated technical capabilities include bioconjugation and ADC manufacturing, nanovectorisation and scale-up of nanodrugs, host cell protein (HCP) risk management, and immunoassay / ELISA development. These capabilities are delivered within an integrated project management framework that covers CMC development, tech transfer, and regulatory support, reducing the need for clients to engage multiple vendors.
Commercially, GTP Bioways operates as a B2B service provider under a sales-led, professional-services model with negotiated, project-based, milestone-driven engagements. It targets biopharmaceutical and biotechnology companies, including both startups and established biotechs, as well as research non-profits, in markets spanning Europe and beyond. In November 2024 the company was acquired by Italian pharmaceutical group Olon and now operates under the Olon France brand. CEO Alain Sainsot leads the subsidiary, which remains the group's biologics CDMO platform for high-potency and innovative biologics.
GTP Bioways firmographics
Firmographics- Name
- GTP Bioways
- Legal name
- GTP Bioways
- Website
- https://gtp-bioways.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- French biologics CDMO headquartered in Toulouse offering end-to-end development, GMP manufacturing, and fill-finish services for monoclonal antibodies, recombinant proteins, ADCs, and nanodrugs to biopharma and biotech clients; acquired by Olon Group in November 2024 and rebranded Olon France.
- Ownership category
- akta.pro rank
GTP Bioways industry classification
Industry- Product category
- Biologics Contract Development and Manufacturing (CDMO)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where GTP Bioways is headquartered
LocationHeadquarters
- HQ city
- Toulouse
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
GTP Bioways business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development & Manufacturing Services: GTP Bioways generates revenue through providing end-to-end contract development and manufacturing services for biologics. Services span R&D, process development, analytical development, GMP manufacturing, and fill & finish. Revenue is project-based with milestone-driven payments throughout the development and manufacturing lifecycle.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
GTP Bioways product offering
Product offeringCore offering
GTP Bioways is a French Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics development and GMP manufacturing services for biopharmaceutical companies. Its offering spans late discovery services, cell line and strain development, process development, analytical development, GMP manufacturing of monoclonal antibodies, recombinant proteins, bispecifics, antibody-drug conjugates and nanodrugs, plus in-house aseptic fill & finish and project management. The company serves biotech and pharma clients globally, leveraging multiple expression systems (mammalian CHO, microbial E. coli and P. pastoris, and insect cells).
Product overview
GTP Bioways is a customer-centric, science-driven Contract Development and Manufacturing Organization (CDMO) offering a unified continuum of services for manufacturing innovative biologics and therapies. The company's integrated portfolio includes Late Discovery Services, Process Development (mammalian, microbial, bioconjugates, nanodrugs), GMP Manufacturing, Analytical Development, Fill & Finish, and Project Management services. The company specializes in five key therapeutic molecule types: Monoclonal Antibodies (mAbs), Recombinant Proteins, Bispecifics, Antibody-Drug Conjugates (ADCs), and Nanodrugs. With over 20 years of CDMO experience and facilities in France (Saint-Julien, Toulouse, Labège, Veyre-Monton), the company supports clients from R&D through commercial production.
Differentiator
Problem solved
Functional benefit
Products and services
- Late Discovery Services Early-stage research services including antibody services, custom protein and antibody production across multiple expression systems (E. coli, P. Pastoris, mammalian cells, insect cells) for R&D studies supporting biopharma clients.
- Process Development Services Comprehensive process development for manufacturing biologics including CHO cell line development, microbial strain development, bioconjugate process development, and nanodrug process development including nanovectorisation and scale-up.
- GMP Manufacturing GMP facilities manufacturing preclinical, clinical, and small commercial batches including mammalian manufacturing, microbial GMP manufacturing, bioconjugates/ADC manufacturing, and nanodrug GMP manufacturing.
- Analytical Development Phase-appropriate analytical method development for mammalian, microbial, and bioconjugate manufacturing, including formulation development, host cell protein analysis, and immunoassay/ELISA development.
- Fill and Finish In-house aseptic filling services supporting liquid drug product manufacturing, accelerating paths to clinic and market for innovative therapies.
- Project Management Expert scientific team guidance through every step of CMC journey including tech transfer, regulatory support, and client-centric CDMO approach from project initiation to completion.
- Monoclonal Antibodies (mAbs) Services Specialized R&D and manufacturing services for monoclonal antibody-based therapeutics using mammalian (CHO) expression systems.
- Antibody-Drug Conjugates (ADCs) Services Bioconjugate process development and GMP manufacturing for antibody-drug conjugates, enhancing capabilities in high-potency API sector.
- Nanodrugs Services Nanodrug process development and GMP manufacturing including nanovectorisation for innovative nanoscale therapeutics.
Quantifiable outcome
- 20+ years of CDMO experience helping customers develop and manufacture innovative therapies
- +1 more outcomes
Companies that use GTP Bioways
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles3 records
GTP Bioways technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
GTP Bioways partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Olon GroupflagshipOlon Group, an Italian pharmaceutical company, acquired GTP Bioways Group in November 2024. This acquisition enhances Olon's capabilities in biologics CDMO services, particularly in R&D and manufacturing of biologics including monoclonal antibodies and ADCs. The acquisition strengthens Olon's position in the high-potency API sector and represents a strategic expansion into high-tech biotech services.
Scale indicators2 records
Recent moves5 records
Expansion highlights6 records
GTP Bioways competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: World's largest contract biologics CDMO offering mammalian and microbial expression, cell and gene therapy, and fill & finish at mega-scale. Comparable as a direct competitor for outsourced biologics development and GMP manufacturing, though Lonza operates at much greater scale and broader modality coverage.
- Samsung Biologics: Large-scale biologics CDMO with multiple mega-plants serving mammalian-based biologics manufacturing. Comparable as a competitor for outsourced mAb and recombinant protein GMP production, especially at commercial scale.
- WuXi Biologics: Global biologics CDMO with end-to-end services and large-scale mammalian manufacturing capacity. Comparable as a competing outsourced biologics manufacturer, though at much larger scale and broader footprint.
Direct peers
- AGC Biologics: Mid-to-large biologics CDMO with mammalian and microbial expression systems plus cell and gene therapy capabilities. Closely comparable in scale, multi-platform offering, and target customer base of biotech and biopharma clients.
- Rentschler Biologics: Germany-based mid-size biologics CDMO specialising in mammalian cell-based recombinant protein and antibody development and manufacturing. Closely comparable as a European, mid-sized, science-driven biologics CDMO serving innovative biotech clients.
- Biovian: European (Finnish) biologics CDMO offering microbial and mammalian-based GMP manufacturing for viral vectors, recombinant proteins, and mAbs. Comparable as a smaller, science-led CDMO serving biotech clients across Europe.
- Polpharma Biologics: European biologics CDMO offering cell line development, process development, and GMP manufacturing of biosimilars and innovative biologics. Comparable in offering and customer base of biotech and biopharma clients.
- Halix: Dutch biologics CDMO focused on mammalian cell-based GMP manufacturing, fill & finish, and viral vectors. Comparable as a mid-size European CDMO with end-to-end biologics services for biotech clients.
- Cobra Biologics (Charles River): CDMO offering biologics, viral vector, and plasmid DNA development and GMP manufacturing, now part of Charles River Laboratories. Comparable as a mid-size European CDMO with microbial and mammalian capabilities serving biotech clients.
Others
- Olon Group: Italian pharmaceutical CDMO (and parent of GTP Bioways since November 2024) with strong small-molecule API and high-potency API capabilities. Adjacent/complementary rather than direct: represents the strategic acquirer and the broader CDMO ecosystem GTP Bioways now operates within.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
GTP Bioways social profiles
Digital presenceGTP Bioways financial estimates
Financial estimateRevenue estimate
Valuation estimate
GTP Bioways leadership team
Management profileNumber of profiles
Profiles1 record
GTP Bioways funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GTP Bioways M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GTP Bioways
What does GTP Bioways do?
GTP Bioways is a French Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics development and GMP manufacturing services for biopharmaceutical companies. Its offering spans late discovery services, cell line and strain development, process development, analytical development, GMP manufacturing of monoclonal antibodies, recombinant proteins, bispecifics, antibody-drug conjugates and nanodrugs, plus in-house aseptic fill & finish and project management. The company serves biotech and pharma clients globally, leveraging multiple expression systems (mammalian CHO, microbial E. coli and P. pastoris, and insect cells).
Is GTP Bioways a public or private company?
GTP Bioways is a private company. It is classified as corporate owned and is currently acquired.
When was GTP Bioways founded?
GTP Bioways was founded in 2000. It employs 51 to 100 people.
Where is GTP Bioways based?
GTP Bioways is headquartered in Toulouse, France, in the Europe region.
How does GTP Bioways make money?
One revenue line is on record: contract Development & Manufacturing Services.
Who are GTP Bioways's main competitors?
Broad incumbents on record are Lonza Group, Samsung Biologics and WuXi Biologics. Direct peers are AGC Biologics, Rentschler Biologics, Biovian, Polpharma Biologics, Halix and Cobra Biologics (Charles River). Olon Group is listed as an others.
Does GTP Bioways have an API?
No public API is recorded for GTP Bioways.
What industry is GTP Bioways in?
GTP Bioways's product category is Biologics Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 541714 and its SIC code is 8731.